Clinical Trial Opinions in Africa: Semaglutide, Depressed Mice, and More
First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others.
To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them. You can submit a Letter to the Editor here, or find the submission form at the end of any First Opinion essay.
Access to Long-Acting Injectables for HIV Prevention in Africa
In response to the article “Tested in Africa, used in America,” by Mark Siedner and Rochelle Walensky, ViiV Healthcare addresses misconceptions about the availability of cabotegravir long-acting for HIV prevention (CAB LA for PrEP) in sub-Saharan Africa (SSA). ViiV Healthcare highlights the rapid progress made since the medicine’s approval in the U.S., including negotiating a voluntary license to expand capacity and improve affordability in resource-limited settings. By the end of 2023, ViiV Healthcare committed to providing over 1 million doses of CAB LA for PrEP to lower- and middle-income countries, with a focus on SSA. The company is proud of the swift rollout of CAB LA for PrEP in various countries, emphasizing its commitment to addressing the HIV epidemic in the region.
Moreover, ViiV Healthcare discusses its efforts in conducting clinical trials in diverse populations, particularly focusing on communities most impacted by HIV. The company emphasizes its support for participants even after the trials have concluded, showcasing a commitment to providing access to medicines for those in need. By highlighting the importance of addressing the unmet need for HIV prevention options, especially among adolescent girls and young women in SSA, ViiV Healthcare showcases its dedication to making a difference in the fight against HIV.
Compounded Semaglutide and the Cost of Medications
In response to Vishal Khetpal’s article on compounded semaglutide, healthcare professionals share their experiences with providing medications through compounding pharmacies to address cost issues. The effectiveness of compounded medications is noted, with a significant percentage of patients receiving their medications from compounding pharmacies. The discussion highlights the challenges faced in ensuring access to affordable medications for patients battling diseases like diabetes and obesity. The importance of addressing barriers to medication access, such as high costs and insurance limitations, is underscored, emphasizing the need for healthcare providers to advocate for their patients in navigating the complex healthcare system.
Rethinking Antidepressant Research Using Animal Models
Karen S. Greenberg’s call to end the “forced swim test” for antidepressant research sparks a discussion on the limitations of using animal models to mimic human conditions. Healthcare professionals express concerns about the effectiveness of current psychiatric treatments and the need for more innovative approaches to addressing mental health issues. The conversation delves into the necessity of reevaluating traditional research methods and embracing more humane and effective strategies for developing treatments. The focus on enhancing empathy and understanding in healthcare practices is highlighted as a crucial component of providing holistic care to patients.
These responses shed light on the complexities of healthcare practices, from medication access and clinical trial diversity to the ethical considerations of animal research and the importance of empathy in patient care. As the healthcare landscape continues to evolve, it is essential for stakeholders to engage in meaningful discussions and collaborative efforts to improve patient outcomes and address systemic challenges in the industry.
